PBS listing of avelumab

PBS listing of avelumab

From 1 May 2019, the immune checkpoint inhibitor Bavencio® (avelumab) will be listed on the Pharmaceutical Benefits Scheme (PBS) for the first time for the treatment of metastatic merkel cell carcinoma.

Listing of avelumab was recommended for subsidy at the July 2018 meeting of the Pharmaceutical Benefits Advisory Committee (PBAC). Further details relating to prescription, restrictions and clinical criteria will be available on the PBS website by 1 May 2019.